Jiangsu Hengrui Medicine Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.
A turbulent 2021: we are now in our eighth year of reviewing R&D productivity and corporate growth of the top 30 biopharma companies. While 2021 was dominated by the COVID-19 pandemic, biopharma as a whole had a good but not great year.
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd.